Top 10 Medical Stocks To Buy For 2019

tags:CDTX,NXST,RBS,CHKE,EXEL,HQH,RS,CTIC,JST,ATHM,

Media stories about Inogen (NASDAQ:INGN) have been trending somewhat positive on Saturday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inogen earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 47.2867768802667 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Top 10 Medical Stocks To Buy For 2019: Cidara Therapeutics, Inc.(CDTX)

Advisors' Opinion:

• [By Chris Lange]

  Cidara Therapeutics Inc. (NASDAQ: CDTX) shares took a big step back on Monday, despite the firm reporting positive midstage results. Specifically, Cidara reported positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate rezafungin acetate.

• [By Ethan Ryder]

  Cantor Fitzgerald set a $15.00 target price on Cidara Therapeutics (NASDAQ:CDTX) in a report released on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

• [By Stephan Byrd]

  These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

  Get Cidara Therapeutics alerts: Cidara Therapeutics (CDTX) Upgraded to Buy at WBB Securities (americanbankingnews.com) Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara's Rezafungin for the Treatment of Invasive Fungal Infections (finance.yahoo.com) Cidara Therapeutics and Rutgers University awarded $5.5M grant from NIH to develop immunotherapy agents targeting gram-negative bacterial infections (seekingalpha.com) Cidara Therapeutics Announces Offering of Common Stock and Warrants (finance.yahoo.com) Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections (finance.yahoo.com)

  Shares of CDTX stock traded up $0.30 during trading on Wednesday, hitting $5.20. 311,700 shares of the company were exchanged, compared to its average volume of 203,168. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.99 and a current ratio of 5.99. The stock has a market cap of $97.33 million, a P/E ratio of -1.64 and a beta of 2.05. Cidara Therapeutics has a twelve month low of $3.70 and a twelve month high of $8.80.

Top 10 Medical Stocks To Buy For 2019: Nexstar Broadcasting Group Inc.(NXST)

Advisors' Opinion:

• [By Max Byerly]

  Get a free copy of the Zacks research report on Nexstar Media Group (NXST)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Nexstar Media Group Inc (NASDAQ:NXST) insider Andrew Alford sold 150 shares of the company’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $79.71, for a total transaction of $11,956.50. Following the transaction, the insider now owns 1,520 shares of the company’s stock, valued at $121,159.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

• [By Shane Hupp]

  Barrington Research reaffirmed their buy rating on shares of Nexstar Media Group (NASDAQ:NXST) in a report issued on Tuesday. They currently have a $110.00 target price on the stock. Barrington Research also issued estimates for Nexstar Media Group’s Q2 2019 earnings at $1.84 EPS, Q3 2019 earnings at $1.67 EPS, Q4 2019 earnings at $2.07 EPS, Q1 2020 earnings at $1.51 EPS, Q2 2020 earnings at $2.40 EPS, Q3 2020 earnings at $2.96 EPS, Q4 2020 earnings at $4.49 EPS and FY2021 earnings at $9.10 EPS.

• [By Stephan Byrd]

  Nexstar Media Group (NASDAQ:NXST) had its price target cut by B. Riley to $87.00. They currently have a buy rating on the stock.

  Ralph Lauren (NYSE:RL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ralph Lauren outperformed the industry in the past six months backed by robust bottom-line performance in recent quarters. Notably, third-quarter fiscal 2018 marked the company’s 12th consecutive earnings beat while sales lagged estimates after a beat in the previous quarter. Additionally, the company’s Way Forward Plan is on track, and it remains keen on bolstering digital and international presence. Also, the company has been gaining from favorable geographic and channel mix shifts along with lower promotions and reduced product costs. Further, management adjusted fiscal 2018 outlook to account for the positive currency rates, which are likely to aid revenues and operating margins. However, its North America business continues to suffer due to distribution and brand exits, planned reduction in shipments and promotions to enhance the quality of sales, and lower customer demand.”

• [By Ethan Ryder]

  These are some of the headlines that may have impacted Accern Sentiment’s scoring:

  Get Nexstar Media Group alerts: Nexstar Media Group Inc (NXST) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com) Nexstar Media Group Inc (NXST) Insider Sells $11,956.50 in Stock (americanbankingnews.com) Nexstar Media Group (NXST) Cut to “Hold” at Noble Financial (americanbankingnews.com) Nexstar Media Group Inc to Post Q3 2018 Earnings of $1.94 Per Share, Barrington Research Forecasts (NXST) (americanbankingnews.com) Get Active Home Medical and Mobility (wdtn.com)

  Shares of NXST opened at $81.40 on Thursday. Nexstar Media Group has a 52-week low of $56.65 and a 52-week high of $89.75. The company has a debt-to-equity ratio of 2.59, a quick ratio of 2.43 and a current ratio of 2.43. The firm has a market capitalization of $3.57 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.61 and a beta of 1.88.

Top 10 Medical Stocks To Buy For 2019: Royal Bank Scotland plc (RBS)

Advisors' Opinion:

• [By Shane Hupp]

  Royal Bank of Scotland Group (LON:RBS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Financial Group in a research note issued on Friday. They currently have a GBX 341 ($4.46) target price on the financial services provider’s stock. Jefferies Financial Group’s price objective points to a potential upside of 35.32% from the company’s current price.

• [By Lisa Levin] Gainers ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook. vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter. Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales. Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings. MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma. New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor. Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session. Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
• [By Joseph Griffin]

  Shares of Royal Bank of Scotland Group PLC (NYSE:RBS) gapped down before the market opened on Monday . The stock had previously closed at $6.94, but opened at $6.95. Royal Bank of Scotland Group shares last traded at $6.89, with a volume of 19561 shares changing hands.

• [By Shane Hupp]

  Royal Bank of Scotland Group plc (LON:RBS) has been assigned an average rating of “Buy” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is GBX 317.86 ($4.15).

Top 10 Medical Stocks To Buy For 2019: Cherokee Inc.(CHKE)

Advisors' Opinion:

• [By Money Morning News Team]

  The 90% gainer was Cherokee Inc. (NASDAQ: CHKE), whose skyrocketing price was the result of its securing a deal to refinance its corporate debt. The deal is a three-year agreement worth $40 million.

• [By Money Morning Staff Reports]

  Last week's top performing penny stock, Cherokee Inc. (Nasdaq: CHKE), jumped over 90% after the company secured a $40 million three-year financing agreement that will allow the company to refinance its debt.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Cherokee (CHKE)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  Cherokee (NASDAQ:CHKE) released its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.11), RTT News reports. Cherokee had a negative return on equity of 13.63% and a negative net margin of 130.24%. During the same quarter last year, the business posted ($0.07) earnings per share.

• [By Garrett Baldwin]

  Following the June FOMC meeting, silver prices are hovering at very attractive price levels. With interest rates heading higher, it's going to be a very good time for silver hounds to buy on the dip and deliver incredible profits in the months ahead. Learn more right here.

  The Top Stock Market Stories for Thursday On Thursday, the European Central Bank held its meeting in Latvia to discuss the future of its quantitative easing program. The central bank of the world's largest economic bloc said that it will likely end its quantitative easing program in December. This represents an extension beyond the current plan to end the stimulus program in September. ECB President Mario Draghi said the program would be reduced to 15 billion euros each month during the final three months of the year. Yesterday, the U.S. Federal Reserve raised interest rates for the second time in 2018. The central bank said that economic growth has been rising at a solid rate and hinted that it could raise rates two more times this year. Fed Chair Jerome Powell did raise an alarm on Wednesday after stating that companies are holding back on investment due to ongoing concerns about U.S. President Donald Trump's trade policies. Trump is expected to decide this week on whether to proceed with tariffs on about $50 billion in Chinese goods. Trade tensions are heating up again. This morning, China announced it would call off its deal to avoid a trade war if the Trump administration proceeds with tariffs on Friday morning. Tomorrow, the Trump team will decide if it will hit China with tariffs on roughly $50 billion in goods. Stocks to Watch Today: ADBE, CMCSA, TSLA, MSFT Adobe Systems Inc. (Nasdaq: ADBE) will report earnings after the bell Thursday. The software giant is expected to report earnings per share of $1.54 on top of $2.15 billion in revenue. Insider buying is alive and well at Tesla Inc. (Nasdaq: TSLA). Chair and CEO Elon Musk purchased $25 million in company stock, according to a
• [By Max Byerly]

  Headlines about Cherokee (NASDAQ:CHKE) have trended positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cherokee earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.2075854049616 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Top 10 Medical Stocks To Buy For 2019: Exelixis, Inc.(EXEL)

Advisors' Opinion:

• [By Stephan Byrd]

  Wedbush Securities Inc. purchased a new position in shares of Exelixis (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,215 shares of the biotechnology company’s stock, valued at approximately $315,000.

• [By Brian Orelli]

  Shares of Exelixis (NASDAQ:EXEL) have jumped 9.8% as of 11:47 a.m. EDT Thursday, having been up as much as 13% earlier, after the biotech released solid second-quarter earnings after the bell yesterday. The company continues to expand sales of its lead drug, Cabometyx, assuaging investors' fears that competition might cut into the drug's growth.

• [By Sean Williams]

  After running a screen for healthcare stocks with a PEG ratio below 1 (courtesy of Yahoo! Finance), the following 13 were all that remained:

  Innoviva (NASDAQ:INVA): 0.42 PEG ratio Celgene (NASDAQ:CELG): 0.54 Mallinckrodt (NYSE:MNK): 0.59 Exelixis (NASDAQ:EXEL): 0.60 Global Cord Blood Corp.: 0.72 AbbVie: 0.75 Vertex Pharmaceuticals: 0.80 DaVita: 0.80 Supernus Pharmaceuticals: 0.80 Mednax: 0.82 MiMedx Group: 0.88 CIGNA: 0.93 Medpace Holdings: 0.95

  Image source: Getty Images.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Exelixis (EXEL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 3,663 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $21.61, for a total transaction of $79,157.43. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Top 10 Medical Stocks To Buy For 2019: Tekla Healthcare Investors(HQH)

Advisors' Opinion:

• [By Max Byerly]

  Tekla Healthcare Investors (NYSE:HQH) announced a quarterly dividend on Monday, August 20th, Wall Street Journal reports. Shareholders of record on Tuesday, August 28th will be given a dividend of 0.47 per share by the financial services provider on Friday, September 28th. This represents a $1.88 dividend on an annualized basis and a yield of 8.29%. The ex-dividend date of this dividend is Monday, August 27th.

• [By Logan Wallace]

  Bank of Nova Scotia cut its stake in shares of Tekla Healthcare Investors (NYSE:HQH) by 19.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,440 shares of the financial services provider’s stock after selling 17,077 shares during the period. Bank of Nova Scotia owned about 0.17% of Tekla Healthcare Investors worth $1,493,000 at the end of the most recent quarter.

Top 10 Medical Stocks To Buy For 2019: Reliance Steel & Aluminum Co.(RS)

Advisors' Opinion:

• [By Shane Hupp]

  Russell Investments Group Ltd. raised its position in shares of Reliance Steel & Aluminum Co (NYSE:RS) by 10.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 294,218 shares of the industrial products company’s stock after buying an additional 27,641 shares during the quarter. Russell Investments Group Ltd. owned 0.41% of Reliance Steel & Aluminum worth $25,796,000 at the end of the most recent quarter.

• [By Shane Hupp]

  Reliance Steel & Aluminum Co (NYSE:RS) hit a new 52-week high and low on Thursday . The company traded as low as $97.41 and last traded at $94.18, with a volume of 15817 shares trading hands. The stock had previously closed at $96.27.

• [By Logan Wallace]

  Shares of Reliance Steel & Aluminum Co (NYSE:RS) have been assigned an average rating of “Hold” from the twelve analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $91.88.

Top 10 Medical Stocks To Buy For 2019: CTI BioPharma Corp.(CTIC)

Advisors' Opinion:

• [By Joseph Griffin]

  Shares of CTI BioPharma Corp (NASDAQ:CTIC) have received an average recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.10.

• [By Brian Feroldi]

  In response to the company sharing a clinical update, shares of CTI BioPharma (NASDAQ:CTIC), a clinical-stage biotech focused on blood-related cancers, fell 13% as of 12:05 p.m. EDT on Monday.

• [By Steve Symington]

  Nevertheless, several individual stocks failed to keep up. Read on to see why CTI BioPharma (NASDAQ:CTIC), PetMed Express (NASDAQ:PETS), and Pfizer (NYSE:PFE) each slumped today.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on CTI BioPharma (CTIC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks To Buy For 2019: Jinpan International Limited(JST)

Advisors' Opinion:

• [By Joseph Griffin]

  JOST Werke AG (ETR:JST) has earned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is €49.33 ($57.36).

• [By Max Byerly]

  Hauck & Aufhaeuser set a €58.00 ($67.44) target price on JOST Werke (ETR:JST) in a report issued on Wednesday. The brokerage currently has a buy rating on the stock.

• [By Joseph Griffin]

  Deutsche Bank set a €46.00 ($53.49) price target on JOST Werke (ETR:JST) in a research report sent to investors on Friday. The firm currently has a buy rating on the stock.

• [By Joseph Griffin]

  Warburg Research set a €47.00 ($55.95) price target on JOST Werke (ETR:JST) in a report published on Friday. The firm currently has a buy rating on the stock.

• [By Logan Wallace]

  A number of firms have modified their ratings and price targets on shares of JOST Werke (ETR: JST) recently:

  5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 5/25/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock. 5/24/2018 – JOST Werke was given a new €45.00 ($52.33) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock. 5/8/2018 – JOST Werke was given a new €46.00 ($53.49) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock. 4/4/2018 – JOST Werke was given a new €47.00 ($54.65) price target on by analysts at Warburg Research. They now have a “buy” rating on the stock.

  Shares of JOST Werke traded down €0.15 ($0.17), hitting €38.10 ($44.30), during mid-day trading on Friday, according to MarketBeat. 8,510 shares of the company’s stock were exchanged, compared to its average volume of 35,469. JOST Werke AG has a 52 week low of €27.20 ($31.63) and a 52 week high of €47.50 ($55.23).

Top 10 Medical Stocks To Buy For 2019: Autohome Inc.(ATHM)

Advisors' Opinion:

• [By Ethan Ryder]

  Raymond James & Associates reduced its stake in shares of Autohome Inc (NYSE:ATHM) by 3.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,347 shares of the information services provider’s stock after selling 7,721 shares during the quarter. Raymond James & Associates owned 0.19% of Autohome worth $23,164,000 at the end of the most recent quarter.

• [By Joseph Griffin]

  These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

  Get Autohome alerts: Dow Jones Falls Before Trump’s Iran Decision; These 2 IBD 50 Stocks Jump (investors.com) Autohome Quarterly Earnings Beat Estimates, Guides Higher (finance.yahoo.com) Autohome (ATHM) Posts Earnings Results, Beats Expectations By $0.11 EPS (americanbankingnews.com) Earnings Reaction History: Autohome Inc., 44.4% Follow-Through Indicator, 4.6% Sensitive (nasdaq.com) BRIEF-Autohome Reports Qtrly Earnings Per Share Of RMB 4.05 (reuters.com)

  Several analysts have recently commented on the stock. ValuEngine raised shares of Autohome from a “hold” rating to a “buy” rating in a research report on Wednesday, April 11th. Zacks Investment Research raised shares of Autohome from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a research report on Monday, March 12th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $73.97.

• [By Leo Sun]

  Tencent's and JD's investments in Bitauto, which date back over three years, allow the two companies to expand their ecosystems into the online automotive market. By tethering itself to Tencent's WeChat and JD's online marketplace, Bitauto widens its moat against Autohome (NYSE:ATHM), its primary rival.

• [By Motley Fool Transcribers]

  Autohome Inc  (NYSE:ATHM)Q4 2018 Earnings Conference CallFeb. 26, 2019, 7:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Autohome (ATHM)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com